摘要
目的:研究瑞舒伐他汀联合替格瑞洛在急性心肌梗死经皮冠状动脉介入治疗患者中的应用。方法:选取本院2019年7月-2020年7月接收的60例行PCI治疗的急性心肌梗死患者作为本次研究对象,通过电脑随机方式将其分为观察组及对照组,每组30例。对照组采用替格瑞洛进行治疗,而观察组应用瑞舒伐他汀联合替格瑞洛进行治疗。对比分析两组临床疗效、治疗前后左心射血分数(LVEF)、左心室舒张末期内径(LVEDD)、脑钠肽(BNP)水平、血清指标和并发症发生率。结果:相较于对照组,观察组治疗总有效率明显更高(P<0.05);相较于对照组,观察组治疗后LVEF、LVEDD、BNP水平优于对照组(P<0.05);观察组治疗后血清指标水平均低于对照组(P<0.05);相较于对照组,观察组并发症发生率明显更低(P<0.05)。结论:针对急性心肌梗死患者而言,在治疗的过程中采用瑞舒伐他汀联合替格瑞洛进行治疗具有较高的临床价值,可以改善临床效果的同时,有效降低患者的并发症发生率,可以满足临床治疗需要。
Objective:To study and analyze the clinical effect of Rosuvastatin combined with Ticagrelor in patients undergoing percutaneous coronary intervention for acute myocardial infarction(PCI).Method:A total of 60 patients with acute myocardial infarction who underwent PCI treatment in our hospital from July 2019 to July 2020 were selected as the subjects of this study,and they were divided into observation group and control group by computer,30 cases in each group.The control group was treated with Ticagrelor,while the observation group was treated with Rosuvastatin combined with Ticagrelor.The clinical effect,left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD)and brain natriuretic peptide(BNP)levels,serum indexes before and after treatment,incidence of complications were compared and analyzed between the two groups.Result:Compared with the control group,the treatment total efficiency of the observation group was significantly higher(P<0.05);compared with the control group,the levels of LVEF,LVEDD,BNP of the observation group were better after treatment(P<0.05);and the levels of serum indexes in the observation group were lower than those in the control group after treatment(P<0.05);compared with the control group,the incidence of complications in the observation group was significantly lower(P<0.05).Conclusion:For patients with acute myocardial infarction,the treatment of Rosuvastatin combined with Ticagrelor in the process of treatment has high clinical value,which can improve the clinical effect and effectively reduce the incidence of complications in patients,which can meet the needs of clinical treatment.
作者
凌洪奖
LING Hongjiang(Pingguo People’s Hospital,Pingguo 531400,China)
出处
《中外医学研究》
2021年第30期133-135,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
